G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte

J Leukoc Biol. 2004 Dec;76(6):1214-9. doi: 10.1189/jlb.0504278. Epub 2004 Sep 2.

Abstract

To study the early stages of development from stem cells of the CD56+ cell population [which includes natural killer (NK) cells], granulocyte-colony stimulating factor-mobilized peripheral blood CD34+ cells from healthy donors were sorted to >99% purity and cultured in the presence of stem cell factor and interleukin (IL)-2. After 3 weeks in culture, the majority of cells acquired CD33, with or without human leukocyte antigen-DR and CD14. In 20 stem cell donors tested, 8.7 +/- 8.8% of cells were CD56+. Two major CD56+ subsets were identified: CD56(bright), mainly CD33- cells (7+/-10%, n=11) with large, granular lymphocyte morphology, and CD56dim, mainly CD33+ (2.5+/-2, n=11) cells with macrophage morphology. The CD56bright population had cytoplasmic granzyme A but lacked killer inhibitory receptor, suggesting they were immature NK cells. The CD56dim, CD33+, population lacked NK markers. They may represent a minor subset of normal monocytes at a developmental stage comparable with the rare CD56+ CD33+ hybrid myeloid/NK cell leukemia. Consistent with a monocyte nature, CD56dimCD33+ proliferated and produced a variety of cytokines upon lipopolysaccharide stimulation, including IL-8, IL-6, monocyte chemoattractant protein-1, and macrophage-derived chemokine but not interferon-gamma. In a short-term cytotoxicity assay, they failed to kill but powerfully inhibited the proliferation of the NK-resistant cell line P815. The generation of CD56+ cells was negatively regulated by hyaluronic acid and IL-4, indicating that extracellular matrix may play an important role in the commitment of CD34+ cells into CD56 myeloid and lymphoid lineages.

MeSH terms

  • Antigens, CD / immunology
  • Antigens, CD34 / immunology*
  • Antigens, Differentiation, Myelomonocytic / immunology
  • Biomarkers
  • CD56 Antigen / immunology*
  • Cell Differentiation / drug effects
  • Cell Differentiation / immunology*
  • Cell Lineage / drug effects
  • Cell Lineage / immunology
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cytokines / biosynthesis
  • Cytotoxicity Tests, Immunologic
  • Extracellular Matrix / immunology
  • Extracellular Matrix / metabolism
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granzymes
  • Humans
  • Hyaluronic Acid / metabolism
  • Hyaluronic Acid / pharmacology
  • Immunophenotyping
  • Interleukin-2 / pharmacology
  • Killer Cells, Natural / cytology
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology*
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Lymphocytes / cytology
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Macrophages / cytology
  • Macrophages / drug effects
  • Macrophages / immunology
  • Monocytes / cytology
  • Monocytes / drug effects
  • Monocytes / immunology*
  • Myeloid Progenitor Cells / cytology
  • Myeloid Progenitor Cells / drug effects
  • Myeloid Progenitor Cells / immunology*
  • Serine Endopeptidases / metabolism
  • Sialic Acid Binding Ig-like Lectin 3
  • Stem Cell Factor / pharmacology

Substances

  • Antigens, CD
  • Antigens, CD34
  • Antigens, Differentiation, Myelomonocytic
  • Biomarkers
  • CD33 protein, human
  • CD56 Antigen
  • Cytokines
  • Interleukin-2
  • Sialic Acid Binding Ig-like Lectin 3
  • Stem Cell Factor
  • Granulocyte Colony-Stimulating Factor
  • Hyaluronic Acid
  • Granzymes
  • Serine Endopeptidases
  • GZMA protein, human